Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)

Authors

• Kenneth H. Mayer, The Fenway Institute, Fenway Health, Harvard Medical School, Harvard University, 1340 Boylston St, 02215, Boston, MA, United States. kmayer@fenwayhealth.org.
• Krista Yuhas, Statistical Center for HIV/AIDS Research (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
• K Rivet Amico, University of Michigan School of Public Health, Ann Arbor, MI, United States.
• Timothy Wilkin, Weill Cornell Medicine, New York, NY, United States.
• Raphael J. Landovitz, UCLA Center for Clinical AIDS Research & Education, Los Angeles, CA, United States.
• Paul Richardson, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
• Mark A. Marzinke, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
• Craig W. Hendrix, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
• Susan H. Eshleman, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
• Leslie M. Cottle, , Seagen, Bothell, WA, United States.
• Cheryl Marcus, HIV Clinical Trials Unit, University of North Carolina, Chapel Hill, NC, United States.
• Wairimu Chege, Clinical Prevention Research Branch, Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States.
• Alex R. Rinehart, Global HIV Prevention Strategy, ViiV Healthcare - Research Triangle Park, Research Triangle Park, NC, United States.
• James F. Rooney, Medical Affairs, Gilead Sciences, 12. FHI 360, Foster City, Durham, CA, NC, United States.
• Philip Andrew, , FHI 360, Durham, NC, United States.
• Robert A. Salata, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.
• Manya Magnus, Milken Institute School of Public Health, George Washington University, Washington, DC, United States.
• Jason E. Farley, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
• Albert Y. Liu, San Francisco Department of Public Health, Bridge HIV, San Francisco, CA, United States.
• Ian Frank, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.
• Ken Ho, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
• Jorge Santana, University of Puerto Rico, San Juan, Puerto Rico.
• Joanne D. Stekler, University of Washington School of Medicine, Seattle, WA, United States.
• Ying Q. Chen, Statistical Center for HIV/AIDS Research (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
• Marybeth McCauley, , FHI 360, Durham, NC, United States.
• Roy M. Gulick, Weill Cornell Medicine, New York, NY, United States.

Document Type

Journal Article

Publication Date

6-10-2022

Journal

AIDS and behavior

DOI

10.1007/s10461-022-03736-z

Keywords

HIV prevention; MSM; Maraviroc; PrEP; Tenofovir

Abstract

HPTN 069/ACTG 5305 was designed to evaluate potential new PrEP regimens that included maraviroc, tenofovir disoproxil fumarate, and/or emtricitabine. The current analyses assessed antiretroviral (ARV) plasma concentrations in relation to sexual behavior in 224 cisgender men who have sex with men and 2 transgender women at risk for HIV. Poisson generalized estimating equations (GEE) regression were used to test for associations between self-reported sexual behavior, sociodemographic, behavioral variables, and study drug levels The median (IQR) age was 30 [25, 37] years old; 48.2% had completed college; 27.4% were Black and 21.7% Latino. At weeks 24 and 48, one third of participants reported condomless anal sex (CAS) in the prior month with more than one partner. CAS was associated with daily ARV drug use (χ = 12.64, p = 0.002). Older individuals and those with greater education were more likely to ingest ARV drugs daily (χ = 9.36, p = 0.009 and χ = 8.63, p = 0.013, respectively), while neither race nor ethnicity was associated with daily ARV drug use. Participants who reported recent condomless anal sex and/or advanced education had higher rates of daily ARV drug use. These data support the need for ongoing adherence counseling in clinical trials of new PrEP modalities.

APA Citation

Mayer, Kenneth H.; Yuhas, Krista; Amico, K Rivet; Wilkin, Timothy; Landovitz, Raphael J.; Richardson, Paul; Marzinke, Mark A.; Hendrix, Craig W.; Eshleman, Susan H.; Cottle, Leslie M.; Marcus, Cheryl; Chege, Wairimu; Rinehart, Alex R.; Rooney, James F.; Andrew, Philip; Salata, Robert A.; Magnus, Manya; Farley, Jason E.; Liu, Albert Y.; Frank, Ian; Ho, Ken; Santana, Jorge; Stekler, Joanne D.; Chen, Ying Q.; McCauley, Marybeth; and Gulick, Roy M., "Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)" (2022). GW Authored Works. Paper 1132.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1132

Department

Epidemiology